Immunogenicity after switching from reference infliximab to biosimilar in children with Crohn's disease

被引：0
|
作者：
Sieczkowska, J. [1 ]
Jarzebicka, D. [1 ]
Oracz, G. [1 ]
Meglicka, M. [1 ]
Dadalski, M. [1 ]
Kierkus, J. [1 ]
机构：
[1] Childrens Mem Hlth Inst, Dept Gastroenterol Hepatol Feeding Disorders & Pa, Warsaw, Poland
来源：
JOURNAL OF CROHNS & COLITIS | 2016年 / 10卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P617
引用
收藏
页码：S413 / S414
页数：2
相关论文
共 50 条
  • [11] Clinical and Immunogenicity Outcomes after Switching Treatment from Innovator Infliximab to Biosimilar Infliximab in Rheumatic Diseases in Daily Clinical Practice
    Tweehuysen, L.
    van den Bemt, B. J. F.
    van Ingen, I. L.
    de Jong, A. J. L.
    van der Laan, W. H.
    van den Hoogen, F. H. J.
    den Broeder, A. A.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [12] ABP 710, a Biosimilar to Infliximab Reference Product: Supporting Extrapolation of Indications With a Focus on Crohn's Disease
    Reinisch, Walter
    Halder, Smita
    Khan, Waliul I.
    Wang, Xuanyu
    Kuhns, Scott
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S1678 - S1679
  • [13] Efficacy of induction and 1 year maintenance therapy with biosimilar infliximab for children with Crohn's disease
    Sieczkowska-Golub, Joanna
    Jarzebicka, Dorota
    Dadalski, Maciej
    Meglicka, Monika
    Oracz, Grzegorz
    Kierkus, Jaroslaw
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 182 - 182
  • [14] Efficacy and safety of switching from reference infliximab to biosimilar infliximab in patients with inflammatory bowel disease: first French experience
    Soret, P. -A.
    Prieux-Klotz, C.
    Avouac, J.
    Molto, A.
    Dior, M.
    Brieau, B.
    Dreanic, J.
    Camus, M.
    Barret, M.
    Coriat, R.
    Conort, O.
    Chast, F.
    Goulvestre, C.
    Le Jeunne, C.
    Dougados, M.
    Nahon, S.
    Chaussade, S.
    Abitbol, V.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S318 - S319
  • [15] EFFICACY AND SAFETY OF SWITCHING FROM REFERENCE INFLIXIMAB TO BIOSIMILAR INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: FIRST FRENCH EXPERIENCE
    Soret, Pierre-Antoine
    Prieux-Klotz, Caroline
    Avouac, Jerome
    Molto, Anna
    Dior, Marie
    Brieau, Bertrand
    Dreanic, Johann
    Camus, Marine
    Barret, Maximilien
    Coriat, Romain
    Conort, Ornella
    Chast, FranOois
    Goulvestre, Claire
    Le Jeunne, Claire
    Dougados, Maxime
    Nahon, Stephane
    Chaussade, Stanislas
    Abitbol, Vered
    GASTROENTEROLOGY, 2017, 152 (05) : S402 - S402
  • [16] Elective Switching from Infliximab to Adalimumab in Stable Crohn's Disease
    Hoentjen, Frank
    Haarhuis, Bertram J. T.
    Drenth, Joost P. H.
    de Jong, Dirk J.
    INFLAMMATORY BOWEL DISEASES, 2013, 19 (04) : 761 - 766
  • [17] Infliximab biosimilar CT-P13 in Crohn's disease
    Gecse, Krisztina B.
    D'Haens, Geert R.
    LANCET, 2019, 393 (10182): : 1671 - 1672
  • [18] Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease
    van Hoeve, Karen
    Dreesen, Erwin
    Hoffman, Ilse
    Van Assche, Gert
    Ferrante, Marc
    Gils, Ann
    Vermeire, Severine
    THERAPEUTIC DRUG MONITORING, 2019, 41 (03) : 317 - 324
  • [19] Serum sickness-like disease after switching to biosimilar infliximab
    Scherlinger, Marc
    Schaeverbeke, Thierry
    Truchetet, Marie-Elise
    RHEUMATOLOGY, 2017, 56 (11) : 2032 - 2034
  • [20] COMPARISON OF IMMUNOGENICITY OF BIOSIMILAR INFLIXIMAB AND ORIGINATOR INFLIXIMAB IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE IN REAL LIFE SETTING
    Wahid, A.
    Muhammed, R.
    GUT, 2017, 66 : A263 - A263
12345